Michael G Katz1, Anthony S Fargnoli1, Richard D Williams1, Nury M Steuerwald2, Alice Isidro1, Anna V Ivanina3, Inna M Sokolova3, Charles R Bridges4. 1. Sanger Heart and Vascular Institute, Cannon Research Center, Carolinas Healthcare System, Charlotte, NC. 2. Molecular Biology Core Facility, Cannon Research Center, Carolinas Healthcare System, Charlotte, NC. 3. Department of Biological Sciences, University of North Carolina Charlotte, Charlotte, NC. 4. Sanger Heart and Vascular Institute, Cannon Research Center, Carolinas Healthcare System, Charlotte, NC. Electronic address: Charles.Bridges@carolinashealthcare.org.
Abstract
OBJECTIVE: Therapeutic safety and efficacy are the basic prerequisites for clinical gene therapy. We investigated the effect of high-dose molecular cardiac surgery with recirculating delivery (MCARD)-mediated adeno-associated virus 9 (AAV9)/sarcoplasmic reticulum Ca(2+) adenosine triphosphatase (SERCA2a) gene delivery on clinical parameters, oxidative stress, humoral and cellular immune responses, and cardiac remodeling. METHODS: Ischemic cardiomyopathy was generated in a sheep model. The sheep were assigned to 1 of 2 groups: control (n = 10) and study (MCARD, n = 6). The control group underwent no intervention and the study group received 10(14) genome copies of AAV9/SERCA2a 4 weeks after infarction. RESULTS: Our ischemic model produced reliable infarcts leading to heart failure. The baseline ejection fraction in the MCARD group was 57.6% ± 1.6% versus 61.2% ± 1.9% in the control group (P > .05). At 12 weeks after infarction, the MCARD group had superior left ventricular function compared with the control group: stroke volume index, 46.6 ± 1.8 versus 35.8 ± 2.5 mL/m(2) (P < .05); ejection fraction, 46.2% ± 1.9% versus 38.7% ± 2.5% (P < .05); and left ventricular end-systolic and end-diastolic dimensions, 41.3 ± 1.7 versus 48.2 ± 1.4 mm and 51.2 ± 1.5 versus 57.6 ± 1.7 mm, respectively (P < .05). The markers of oxidative stress were significantly reduced in the infarct zone in the MCARD group. No positive T-cell-mediated immune response was seen in the MCARD group at any point. Myocyte hypertrophy was also significantly attenuated in the MCARD group compared with the control group. CONCLUSIONS: Cardiac overexpression of the SERCA2a gene by way of MCARD is a safe therapeutic intervention. It significantly improves left ventricular function, decreases markers of oxidative stress, abrogates myocyte hypertrophy, arrests remodeling, and does not induce a T-cell-mediated immune response.
OBJECTIVE: Therapeutic safety and efficacy are the basic prerequisites for clinical gene therapy. We investigated the effect of high-dose molecular cardiac surgery with recirculating delivery (MCARD)-mediated adeno-associated virus 9 (AAV9)/sarcoplasmic reticulum Ca(2+) adenosine triphosphatase (SERCA2a) gene delivery on clinical parameters, oxidative stress, humoral and cellular immune responses, and cardiac remodeling. METHODS:Ischemic cardiomyopathy was generated in a sheep model. The sheep were assigned to 1 of 2 groups: control (n = 10) and study (MCARD, n = 6). The control group underwent no intervention and the study group received 10(14) genome copies of AAV9/SERCA2a 4 weeks after infarction. RESULTS: Our ischemic model produced reliable infarcts leading to heart failure. The baseline ejection fraction in the MCARD group was 57.6% ± 1.6% versus 61.2% ± 1.9% in the control group (P > .05). At 12 weeks after infarction, the MCARD group had superior left ventricular function compared with the control group: stroke volume index, 46.6 ± 1.8 versus 35.8 ± 2.5 mL/m(2) (P < .05); ejection fraction, 46.2% ± 1.9% versus 38.7% ± 2.5% (P < .05); and left ventricular end-systolic and end-diastolic dimensions, 41.3 ± 1.7 versus 48.2 ± 1.4 mm and 51.2 ± 1.5 versus 57.6 ± 1.7 mm, respectively (P < .05). The markers of oxidative stress were significantly reduced in the infarct zone in the MCARD group. No positive T-cell-mediated immune response was seen in the MCARD group at any point. Myocyte hypertrophy was also significantly attenuated in the MCARD group compared with the control group. CONCLUSIONS: Cardiac overexpression of the SERCA2a gene by way of MCARD is a safe therapeutic intervention. It significantly improves left ventricular function, decreases markers of oxidative stress, abrogates myocyte hypertrophy, arrests remodeling, and does not induce a T-cell-mediated immune response.
Authors: Michael G Katz; Anthony S Fargnoli; JaBaris D Swain; Catherine E Tomasulo; Michele Ciccarelli; Z Maggie Huang; Joseph E Rabinowitz; Charles R Bridges Journal: J Thorac Cardiovasc Surg Date: 2011-12-03 Impact factor: 5.209
Authors: Christina A Pacak; Cathryn S Mah; Bijoy D Thattaliyath; Thomas J Conlon; Melissa A Lewis; Denise E Cloutier; Irene Zolotukhin; Alice F Tarantal; Barry J Byrne Journal: Circ Res Date: 2006-07-27 Impact factor: 17.367
Authors: Alberto Dominguez-Rodriguez; Pedro Abreu-Gonzalez; Alejandro de la Rosa; Manuel Vargas; Julio Ferrer; Martín Garcia Journal: Int J Cardiol Date: 2005-03-10 Impact factor: 4.164
Authors: J H Gorman; R C Gorman; T Plappert; B M Jackson; Y Hiramatsu; M G St John-Sutton; L H Edmunds Journal: J Thorac Cardiovasc Surg Date: 1998-03 Impact factor: 5.209
Authors: Lawrence T Bish; Kevin Morine; Meg M Sleeper; Julio Sanmiguel; Di Wu; Guangping Gao; James M Wilson; H Lee Sweeney Journal: Hum Gene Ther Date: 2008-12 Impact factor: 5.695
Authors: Federica del Monte; Djamel Lebeche; J Luis Guerrero; Tsuyoshi Tsuji; Angelia A Doye; Judith K Gwathmey; Roger J Hajjar Journal: Proc Natl Acad Sci U S A Date: 2004-03-25 Impact factor: 11.205
Authors: Michael G Katz; Anthony S Fargnoli; Andrew P Kendle; Charles R Bridges Journal: Am J Physiol Heart Circ Physiol Date: 2015-02-15 Impact factor: 4.733
Authors: Michael G Katz; Anthony S Fargnoli; Charles Yarnall; Angel Perez; Alice Isidro; Roger J Hajjar; Charles R Bridges Journal: J Extra Corpor Technol Date: 2018-09
Authors: Terence R Flotte; Eric Daniels; Janet Benson; Jeneé M Bevett-Rose; Kenneth Cornetta; Margaret Diggins; Julie Johnston; Susan Sepelak; Johannes C M van der Loo; James M Wilson; Cheryl L McDonald Journal: Hum Gene Ther Clin Dev Date: 2017-11-27 Impact factor: 5.032
Authors: Michael G Katz; Anthony S Fargnoli; Thomas Weber; Roger J Hajjar; Charles R Bridges Journal: Hum Gene Ther Clin Dev Date: 2017-07-19 Impact factor: 5.032
Authors: Michael G Katz; Anthony S Fargnoli; Andrew P Kendle; Roger J Hajjar; Charles R Bridges Journal: Ann Thorac Surg Date: 2016-01-20 Impact factor: 4.330
Authors: Michael G Katz; Elizabeth Brandon-Warner; Anthony S Fargnoli; Richard D Williams; Andrew P Kendle; Roger J Hajjar; Laura W Schrum; Charles R Bridges Journal: J Thorac Cardiovasc Surg Date: 2015-11-25 Impact factor: 5.209